Early Findings Show Potential Efficacy, Safety of BXCL701, Pembrolizumab for Metastatic PDAC

By Benjamin Weinberg, MD, FACP - Last Updated: March 19, 2025

Benjamin Weinberg, MD, FACP, of Lombardi Comprehensive Center, highlights his latest study presented at the 2024 American Society of Clinical Oncology Annual Meeting investigating the effects of BXCL701 plus pembrolizumab for metastatic pancreatic ductal adenocarcinoma.

Find more ASCO 2024 coverage here.

FOLFIRINOX Can Improve PFS Over Gemcitabine for Patients With Locally Advanced Pancreatic Cancer

Emily MenendezPancreatic Cancer | May 21, 2025

The phase 3 NEOPAN study has shown that FOLFIRINOX can significantly improve PFS compared with gemcitabine.

Neoadjuvant Chemotherapy Shows Promise for Treatment of Patients With Resectable Pancreatic Adenocarcinoma

Jessica GangaPancreatic Cancer | May 16, 2025

Researchers evaluated the use of mFOLFIRINOX for the treatment of patients with resectable pancreatic adenocarcinoma.

Breaking Silos, Building Impact: Dr. Bassel El-Rayes on Advancing Pancreatic and Neuroendocrine Cancer Research

Bassel El-Rayes, MDPancreatic Cancer | April 29, 2025

Dr. El-Rayes reflects on his career in translational research, emphasizing his efforts to expand trial infrastructure.

The Efficacy of PARP Inhibitors for DDR Deficiencies in Metastatic Pancreatic Cancer

James Cleary, MD, PhDPancreatic Cancer | April 17, 2025

Dr. Cleary discusses DDR deficiencies in metastatic pancreatic cancer and reviews the use of PARP inhibitors.

Zenocutuzumab Safety, Efficacy for NRG1 Fusion-Positive Pancreatic Cancer: Low-Grade AEs

Emily MenendezPancreatic Cancer | April 15, 2025

Zenocutuzumab may serve as an effective treatment for NRG1 fusion-positive pancreatic cancer, with low-grade AEs.

Early Findings Show Potential Efficacy, Safety of BXCL701, Pembrolizumab for Metastatic PDAC

Related Posts